Jörg Glatzle
YOU?
Author Swipe
View article: Sexual and Relationship Satisfaction of Ostomy Patients
Sexual and Relationship Satisfaction of Ostomy Patients Open
Sexual satisfaction is a crucial element in overall well-being and life satisfaction, yet individuals with an ostomy face challenges that might significantly impact their self-esteem and sexual experiences, which decreases sexual satisfact…
View article: Data from Phase I Study of Oncolytic Vaccinia Virus GL-ONC1 in Patients with Peritoneal Carcinomatosis
Data from Phase I Study of Oncolytic Vaccinia Virus GL-ONC1 in Patients with Peritoneal Carcinomatosis Open
Purpose: Peritoneal carcinomatosis is common in advanced tumor stages or disease recurrence arising from gastrointestinal cancers, gynecologic malignancies, or primary peritoneal carcinoma. Because current therapies are mostly ineffective,…
View article: Table S2 from Phase I Study of Oncolytic Vaccinia Virus GL-ONC1 in Patients with Peritoneal Carcinomatosis
Table S2 from Phase I Study of Oncolytic Vaccinia Virus GL-ONC1 in Patients with Peritoneal Carcinomatosis Open
Characterization of ascites sample contents based on cytological analyses (patient 01).
View article: Figure S3 from Phase I Study of Oncolytic Vaccinia Virus GL-ONC1 in Patients with Peritoneal Carcinomatosis
Figure S3 from Phase I Study of Oncolytic Vaccinia Virus GL-ONC1 in Patients with Peritoneal Carcinomatosis Open
Cytological analyses of further study patients.
View article: Table S1 from Phase I Study of Oncolytic Vaccinia Virus GL-ONC1 in Patients with Peritoneal Carcinomatosis
Table S1 from Phase I Study of Oncolytic Vaccinia Virus GL-ONC1 in Patients with Peritoneal Carcinomatosis Open
GL-ONC1 shedding analysis (patient 01).
View article: Figure S1 from Phase I Study of Oncolytic Vaccinia Virus GL-ONC1 in Patients with Peritoneal Carcinomatosis
Figure S1 from Phase I Study of Oncolytic Vaccinia Virus GL-ONC1 in Patients with Peritoneal Carcinomatosis Open
Biological verification of calculated GL-ONC1 dosages.
View article: Data from Phase I Study of Oncolytic Vaccinia Virus GL-ONC1 in Patients with Peritoneal Carcinomatosis
Data from Phase I Study of Oncolytic Vaccinia Virus GL-ONC1 in Patients with Peritoneal Carcinomatosis Open
Purpose: Peritoneal carcinomatosis is common in advanced tumor stages or disease recurrence arising from gastrointestinal cancers, gynecologic malignancies, or primary peritoneal carcinoma. Because current therapies are mostly ineffective,…
View article: Figure S4 from Phase I Study of Oncolytic Vaccinia Virus GL-ONC1 in Patients with Peritoneal Carcinomatosis
Figure S4 from Phase I Study of Oncolytic Vaccinia Virus GL-ONC1 in Patients with Peritoneal Carcinomatosis Open
Comparison of 18F-FDG-PET-CT imaging pre-virotherapy versus day 24 post virotherapy.
View article: Table S1 from Phase I Study of Oncolytic Vaccinia Virus GL-ONC1 in Patients with Peritoneal Carcinomatosis
Table S1 from Phase I Study of Oncolytic Vaccinia Virus GL-ONC1 in Patients with Peritoneal Carcinomatosis Open
GL-ONC1 shedding analysis (patient 01).
View article: Figure S1 from Phase I Study of Oncolytic Vaccinia Virus GL-ONC1 in Patients with Peritoneal Carcinomatosis
Figure S1 from Phase I Study of Oncolytic Vaccinia Virus GL-ONC1 in Patients with Peritoneal Carcinomatosis Open
Biological verification of calculated GL-ONC1 dosages.
View article: Table S2 from Phase I Study of Oncolytic Vaccinia Virus GL-ONC1 in Patients with Peritoneal Carcinomatosis
Table S2 from Phase I Study of Oncolytic Vaccinia Virus GL-ONC1 in Patients with Peritoneal Carcinomatosis Open
Characterization of ascites sample contents based on cytological analyses (patient 01).
View article: Figure S2 from Phase I Study of Oncolytic Vaccinia Virus GL-ONC1 in Patients with Peritoneal Carcinomatosis
Figure S2 from Phase I Study of Oncolytic Vaccinia Virus GL-ONC1 in Patients with Peritoneal Carcinomatosis Open
Inflammatory response following GL-ONC1 therapy.
View article: Figure S3 from Phase I Study of Oncolytic Vaccinia Virus GL-ONC1 in Patients with Peritoneal Carcinomatosis
Figure S3 from Phase I Study of Oncolytic Vaccinia Virus GL-ONC1 in Patients with Peritoneal Carcinomatosis Open
Cytological analyses of further study patients.
View article: Figure S2 from Phase I Study of Oncolytic Vaccinia Virus GL-ONC1 in Patients with Peritoneal Carcinomatosis
Figure S2 from Phase I Study of Oncolytic Vaccinia Virus GL-ONC1 in Patients with Peritoneal Carcinomatosis Open
Inflammatory response following GL-ONC1 therapy.
View article: Figure S4 from Phase I Study of Oncolytic Vaccinia Virus GL-ONC1 in Patients with Peritoneal Carcinomatosis
Figure S4 from Phase I Study of Oncolytic Vaccinia Virus GL-ONC1 in Patients with Peritoneal Carcinomatosis Open
Comparison of 18F-FDG-PET-CT imaging pre-virotherapy versus day 24 post virotherapy.
View article: Gastric Ulcer Complications after the Introduction of Proton Pump Inhibitors into Clinical Routine: 20-Year Experience
Gastric Ulcer Complications after the Introduction of Proton Pump Inhibitors into Clinical Routine: 20-Year Experience Open
Background: The aim of this study was to analyze the admissions and the management of peptic ulcer disease (PUD) in a tertiary care surgical center. Methods: We evaluated the medical records of all patients admitted to the University Hospi…
View article: Erratum to “Personalized peptide vaccine-induced immune response associated with long-term survival of a metastatic cholangiocarcinoma patient”
Erratum to “Personalized peptide vaccine-induced immune response associated with long-term survival of a metastatic cholangiocarcinoma patient” Open
Personalized peptide vaccine-induced immune response associated with long-term survival of a metastatic cholangiocarcinoma patientJournal of HepatologyVol. 65Issue 4PreviewCholangiocarcinomas (CCA), heterogeneous malignant epithelial tumor…
View article: Personalized peptide vaccine-induced immune response associated with long-term survival of a metastatic cholangiocarcinoma patient
Personalized peptide vaccine-induced immune response associated with long-term survival of a metastatic cholangiocarcinoma patient Open
Metastatic cholangiocarcinomas, cancers that originate from the liver bile ducts, have very limited treatment options and a fatal prognosis. We describe a novel therapeutic approach in such a patient using a personalized multi-peptide vacc…